Iron, hepatic stellate cells and fibrosis in chronic hepatitis C

被引:34
作者
Rigamonti, C
Andorno, S
Maduli, E
Morelli, S
Pittau, S
Nicosia, G
Boldorini, R
Sartori, M
机构
[1] Univ Piemonte Orientale Amedeo Avogadro, Clin Med Gen, AO Maggiore Carita, I-28100 Novara, Italy
[2] AO Maggiore Carita, Serv Anat & Istol Patol, Novara, Italy
关键词
fibrogenesis; hepatic regeneration; hepatic stellate cells; hepatitis C; iron;
D O I
10.1046/j.1365-2362.2002.0320s1028.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/aims In patients with chronic hepatitis C, hepatic iron concentration correlates with liver fibrosis. However, it is not clear whether this correlation merely reflects the presence of more active disease, or iron exacerbates chronic hepatitis C virus (HCV)-induced damage through activation of hepatic stellate cells and regeneration of hepatocytes. Materials and methods We studied 72 HCV-positive patients, staged according to the Ishak's score system. We measured hepatic iron concentration with spectrophotometry and evaluated the number of hepatic stellate cells (using monoclonal antibody against alpha smooth muscle actin) and proliferating hepatocytes (using monoclonal antibody against Ki67). Iron and ferritin serum levels were also determined. Results Hepatic iron concentration correlated statistically with ferritin serum level (r = 0.59, P < 0.001), with grading (r = 0.47, P < 0.001) and staging (r = 0.5 1, P < 0.001) scores for chronic hepatitis in the whole group of patients. Hepatic iron concentration correlated positively with stellate cell number (r = 0.55, P = 0.004) and Ki67-positive hepatocyte number (r = 0.36, P = 0.08) in patients with chronic hepatitis C and low grading score (< 3). Conclusions In patients with chronic hepatitis C and low grading score, hepatic iron could play a role in the activation of hepatic stellate cells and in the progression of fibrosis.
引用
收藏
页码:28 / 35
页数:8
相关论文
共 49 条
[1]   EFFECTS OF THERAPY WITH INTERFERON-ALPHA ON PERIPHERAL-BLOOD LYMPHOCYTE SUBSETS AND NK ACTIVITY IN PATIENTS WITH CHRONIC HEPATITIS-C [J].
APPASAMY, R ;
BRYANT, J ;
HASSANEIN, T ;
VANTHIEL, DH ;
WHITESIDE, TL .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1994, 73 (03) :350-357
[2]  
Baroni GS, 1998, HEPATOLOGY, V27, P720
[3]   Effects of iron loading on pathogenicity in hepatitis C virus-infected chimpanzees [J].
Bassett, SE ;
Di Bisceglie, AM ;
Bacon, BR ;
Sharp, RM ;
Govindarajan, S ;
Hubbard, GB ;
Brasky, KM ;
Lanford, RE .
HEPATOLOGY, 1999, 29 (06) :1884-1892
[4]   Threshold effect of liver iron content on hepatic inflammation and fibrosis in hepatitis B and C [J].
Beinker, NK ;
Voigt, MD ;
Arendse, M ;
Smit, J ;
Stander, IA ;
Kirsch, RE .
JOURNAL OF HEPATOLOGY, 1996, 25 (05) :633-638
[5]   Iron and chronic viral hepatitis [J].
Bonkovsky, HL ;
Banner, BF ;
Rothman, AL .
HEPATOLOGY, 1997, 25 (03) :759-768
[6]   HUMAN NATURAL-KILLER CELL-LYSIS OF VIRUS-INFECTED CELLS - RELATIONSHIP TO EXPRESSION OF THE TRANSFERRIN RECEPTOR [J].
BORYSIEWICZ, LK ;
GRAHAM, S ;
SISSONS, JGP .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1986, 16 (04) :405-411
[7]   Liver iron concentration and distribution in chronic hepatitis C before and after interferon treatment [J].
Boucher, E ;
Bourienne, A ;
Adams, P ;
Turlin, B ;
Brissot, P ;
Deugnier, Y .
GUT, 1997, 41 (01) :115-120
[8]   LIVER PATHOLOGY IN GENETIC HEMOCHROMATOSIS - A REVIEW OF 135 HOMOZYGOUS CASES AND THEIR BIOCLINICAL CORRELATIONS [J].
DEUGNIER, YM ;
LOREAL, O ;
TURLIN, B ;
GUYADER, D ;
JOUANOLLE, H ;
MOIRAND, R ;
JACQUELINET, C ;
BRISSOT, P .
GASTROENTEROLOGY, 1992, 102 (06) :2050-2059
[9]   Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: A multicenter, prospective, randomized, controlled trial [J].
Di Bisceglie, AM ;
Bonkovsky, HL ;
Chopra, S ;
Flamm, S ;
Reddy, RK ;
Grace, N ;
Killenberg, P ;
Hunt, C ;
Tamburro, C ;
Tavill, AS ;
Ferguson, R ;
Krawitt, E ;
Banner, B ;
Bacon, BR .
HEPATOLOGY, 2000, 32 (01) :135-138
[10]   Hepatitis C [J].
Di Bisceglie, AM .
LANCET, 1998, 351 (9099) :351-355